Back to Sites

Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS

Site Number

30022

Address

33, Boulevard Harry Truman
Port-au-Prince, 6110
Haiti

IMPAACT Members at this Site

Samuel Pierre MD CRS Coordinator

Cynthia Riviere CRS Coordinator

Vanessa Rouzier CRS Leader

Marie-Marcelle Deschamps MD CTU Coordinator

Jean William Pape CTU Principal Investigator

Elsie Jean Study Coordinator

Studies at this Site

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV

DAIDS Number

11884

Research Area

Tuberculosis

Study Status

Closed to Accrual

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

DAIDS Number

12026

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less Than 13 Years of Age with and without HIV

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Enrolling